Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Marcello Rotta, MD, Barry Storer, PhD, Firoozeh Sahebi, MD, Judith A. Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Thoralf Lange, MD, Peter A. McSweeney, MD, Michael Pulsipher, MD, Parameswaran Hari, MD, MS, Richard Thomas Maziarz, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick Appelbaum, MD, William Bensinger, MD, Brenda Sandmaier, MD, PhD, Rainer Storb, MD, David G. Maloney, MD, PhD

Blood (2008) 112 (11): 1130.

https://doi.org/10.1182/blood.V112.11.1130.1130

Published: 2008

Journal Articles

Reversal of Low Chimerism Following Nonmyeloablative (NM) Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusions (DLI).

Monica Thakar, MD, Barry Storer, PhD, Thomas Chauncey, MD, PhD, Michael Pulsipher, MD, David Maloney, MD, PhD, Rainer Storb, MD, Brenda Sandmaier, MD

Blood (2007) 110 (11): 480.

https://doi.org/10.1182/blood.V110.11.480.480

Published: 2007

Journal Articles

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Paul O’Donnell, MD, PhD, Leo Luznik, MD, Heather Symons, MD, Richard Jones, MD, Ted Gooley, PhD, Elizabeth Harrington, MSN, Sandra Warnock, Brenda Sandmaier, MD, Rainer Storb, MD, Ephraim Fuchs, MD

Blood (2006) 108 (11): 3135.

https://doi.org/10.1182/blood.V108.11.3135.3135

Published: 2006

Journal Articles

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

Christoph Kahl, MD, Barry Storer, PhD, Marco Mielcarek, MD, Mike Maris, MD, Brenda Sandmaier, MD, David Maloney, MD, PhD, Thomas Chauncey, MD, Dietger Niederwieser, MD, Peter McSweeney, MD, Benedetto Bruno, MD, Karl Blume, MD, James Wade, MD, Jose Leis, MD, PhD, Emilia Langston, MD, Michael Pulsipher, MD, Edward Agura, MD, Rainer Storb, MD

Blood (2005) 106 (11): 703.

https://doi.org/10.1182/blood.V106.11.703.703

Published: 2005

Journal Articles

Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

Marco Mielcarek, MD, Lauri Burroughs, MD, Wendy Leisenring, PhD, Paul Martin, MD, Razvan Diaconezcu, MD, Brenda Sandmaier, MD, David Maloney, MD, PhD, Thomas Chauncey, MD, PhD, Michael Maris, MD, Judith Shizuru, MD, Karl Blume, MD, Ute Hegenbart, MD, Dietger Niederwieser, MD, Stephen Forman, MD, Benedetto Bruno, MD, Ann Woolfrey, MD, Rainer Storb, MD

Blood (2004) 104 (11): 423.

https://doi.org/10.1182/blood.V104.11.423.423

Published: 2004

Journal Articles

Myeloablative Versus Nonmyeloablative Hemopoietic Cell Transplantation (HCT) for Patients with Myelodysplasia (MDS) or AML with Multilineage Dysplasia Following MDS (tAML).

Bart L. Scott, Michael Maris, Brenda Sandmaier, Barry Storer, Thomas Chauncey, David G. Maloney, Mohamed Sorror, Rainer Storb, H. Joachim Deeg

Blood (2004) 104 (11): 2320.

https://doi.org/10.1182/blood.V104.11.2320.2320

Published: 2004

Journal Articles

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Mohamed Sorror, MD, MSc, Michael Maris, MD, Barry Storer, PhD, Brenda Sandmaier, MD, Monic Stuart, MD, Ute Hegenbart, MD, Edward Agura, MD, Thomas Chauncey, MD, Jose Leis, MD, PhD, Michael Pulsipher, MD, Peter McSweeney, MD, Jerry Radich, MD, James Wade, MD, Benedetto Bruno, MD, Amelia Langston, MD, Dietger Niederwieser, MD, Karl Blume, MD, Rainer Storb, MD, David Maloney, MD, PhD

Blood (2004) 104 (11): 2323.

https://doi.org/10.1182/blood.V104.11.2323.2323

Published: 2004

Journal Articles

Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation.

Sergio Giralt, Brent Logan, Mei-Jei Zhang, Olivia McGaha, Karen Ballen, Christos Emmanouilides, Rajneesh Nath, Pablo Miguel Parker, David Porter, Brenda Sandmaier, Edmund Waller, Juliet Barker, Steven Pavletic, Daniel Weisdorf

Blood (2004) 104 (11): 2751.

https://doi.org/10.1182/blood.V104.11.2751.2751

Published: 2004

Journal Articles

Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation.

Frederic Baron, Michael Maris, Barry Storer, Brenda Sandmaier, Jens Panse, Thomas Chauncey, Mohamed Sorror, Marie Terese Little, David Maloney, Rainer Storb, Shelly Heimfeld

Blood (2004) 104 (11): 2753.

https://doi.org/10.1182/blood.V104.11.2753.2753

Published: 2004

Journal Articles

A Modified Hematopoietic Cell Transplantation (HCT)-Specific-Comorbidity Index.

Mohamed Sorror, MD, MSc, Maris Maris, MD, Frederic Baron, MD, Brenda Sandmaier, MD, David Maloney, MD, PhD, Rainer Storb, MD, Barry Storer, PhD

Blood (2004) 104 (11): 1146.

https://doi.org/10.1182/blood.V104.11.1146.1146

Published: 2004

NARROW

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Reversal of Low Chimerism Following Nonmyeloablative (NM) Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusions (DLI).

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.

Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.

Myeloablative Versus Nonmyeloablative Hemopoietic Cell Transplantation (HCT) for Patients with Myelodysplasia (MDS) or AML with Multilineage Dysplasia Following MDS (tAML).

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation.

Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation.

A Modified Hematopoietic Cell Transplantation (HCT)-Specific-Comorbidity Index.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only